ARID2 (E-3): sc-166117



The Power to Question

BACKGROUND

BAF200 (AT-rich interactive domain-containing protein 2, BRG1-associated factor 200) is a 1,835 amino acid protein encoded by the human gene ARID2. BAF200 is a nuclear protein that belongs to the SWI/SNF family of chromatin-remodeling complexes and contains one ARID domain. It is involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). BAF200 is required for the stability of the BAF (SWI/SNF-A) and PBAF (SWI/SNF-B) chromatin remodeling complexes. It also may be involved in targeting the SWI/SNF complex to different genes.

CHROMOSOMAL LOCATION

Genetic locus: ARID2 (human) mapping to 12q12.

SOURCE

ARID2 (E-3) is a mouse monoclonal antibody raised against amino acids 1134-1316 mapping within an internal region of BAF200 of human origin.

PRODUCT

Each vial contains 200 μ g lgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-166117 X, 200 μ g/0.1 ml.

ARID2 (E-3) is available conjugated to agarose (sc-166117 AC), 500 μ g/ 0.25 ml agarose in 1 ml, for IP; to HRP (sc-166117 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-166117 PE), fluorescein (sc-166117 FITC), Alexa Fluor* 488 (sc-166117 AF488), Alexa Fluor* 546 (sc-166117 AF546), Alexa Fluor* 594 (sc-166117 AF594) or Alexa Fluor* 647 (sc-166117 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor* 680 (sc-166117 AF680) or Alexa Fluor* 790 (sc-166117 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

ARID2 (E-3) is recommended for detection of ARID2 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for ARID2 siRNA (h): sc-96225, ARID2 shRNA Plasmid (h): sc-96225-SH and ARID2 shRNA (h) Lentiviral Particles: sc-96225-V.

ARID2 (E-3) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight (predicted) of ARID2: 197 kDa.


Molecular Weight (observed) of ARID2: 217 kDa.


Positive Controls: ARID2 (h): 293T Lysate: sc-175552, HeLa nuclear extract: sc-2120 or Jurkat nuclear extract: sc-2132.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA







ARID2 (E-3): sc-166117. Western blot analysis of ARID2 expression in non-transfected: sc-117752 (**A**) and human ARID2 transfected: sc-17552 (**B**) 293T whole cell lysates and HeLa (**C**), Jurkat (**D**) and MCF7 (**E**) nuclear extracts.

ARID2 (E-3): sc-166117. Immunofluorescence staining of formalin-fixed Hep G2 cells showing nuclear localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human testis tissue showing nuclear staining of cells in seminiferous ducts and nuclear and cytoplasmic staining of Leydig cells (B).

SELECT PRODUCT CITATIONS

- Kang, D., et al. 2015. EBV BART microRNAs target multiple pro-apoptotic cellular genes to promote epithelial cell survival. PLoS Pathog. 11: e1004979.
- Gurard-Levin, Z.A., et al. 2016. Chromatin regulators as a guide for cancer treatment choice. Mol. Cancer Ther. 15: 1768-1777.
- Meisenberg, C., et al. 2018. Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. Mol. Cell 73: 212-223.
- 4. Pan, J., et al. 2019. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting. Nat. Genet. 51: 618-626.
- Schick, S., et al. 2019. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat. Genet. 51: 1399-1410.
- Inoue, D., et al. 2019. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574: 432-436.
- Wu, M., et al. 2020. MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. Biomed. Pharmacother. 122: 109696.
- Minderjahn, J., et al. 2020. Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. Nat. Commun. 11: 402.
- 9. Shi, H., et al. 2020. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci. Adv. 6: eaaz3440.

RESEARCH USE

For research use only, not for use in diagnostic procedures.